MTRとMTRR遺伝子ポリモルフィズムと膠原腫のリスクとの関連の定量評価
Xu Chen1, Yanping Yao2, Xi Wang3
1Center of Clinical Laboratory, First Affiliated Hospital of Soochow University, 188 Shizi Road, Suzhou, 215006, Jiangsu, People's Republic of China.
Discover oncology
|August 23, 2025
まとめ
MTRR rs1801394のポリモルフィズムは,インド人の群れにおいて,膠原腫から保護する可能性があるが,白人の群れや中国の群れではそうではない. この発見は,膠原腫のリスク予測と 個別化された治療戦略に役立ちます.
科学分野:
- 遺伝学
- 腫瘍学
- 流行病学
背景:
- グリオマの感受性は遺伝的要因に左右される.
- メチオニン合成酵素 (MTR) とメチオニン合成還元酵素 (MTRR) の遺伝子ポリモルフィズムと膠原腫のリスクに関する以前の研究は,矛盾した結果を示した.
- これらのポリモルフィズムの役割を明確にすることは,膠原腫の発達を理解するために不可欠です.
研究 の 目的:
- MTRとMTRR遺伝子ポリモルフィズムと膠原腫のリスクとの関連を調査する.
- これらの遺伝的変異が膠原腫の感受性に与える影響をより明確に理解するためです.
主な方法:
- 主要なデータベースを使用して,包括的な文献レビューが行われました.
- データベースの開始から2025年4月までのデータを収集した.
- データを合成するためにメタ分析技術が採用されました.
主要な成果:
- すべての集団において,MTR rs1805087の多形化と膠原腫のリスクとの間に有意な関連性が見つかりませんでした.
- MTRR rs1801394のポリモルフィズムは,アジア人群におけるグリオマリスクと有意な関連性を示した (p < 0. 05).
結論:
- MTRR rs1801394のポリモルフィズムは,インド人集団では保護因子として作用するが,白人や中国人集団ではそうではない.
- このポリモルフィズムが 潜在的に 膠原腫のリスクを予測する バイオマーカーとして機能します
- パーソナライズされた膠原腫治療の標的にもなります.
関連する概念動画
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:12Relative Risk
Relative risk (RR) is a statistical measure commonly used in epidemiology to compare the likelihood of a particular event occurring between two groups. This metric is important for evaluating the relationship between exposure to a specific risk factor and the probability of a particular outcome. It plays a crucial role in medical research, public health studies, and risk assessment. Relative risk quantifies how much more (or less) likely an event is to occur in an exposed group compared to an...
01:12Hazard Ratio
The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial evaluating a...
For example, in a clinical trial evaluating a...